Search - tctmd.com

Displaying 1 - 20 of 24

Sort: Relevancy | Date

News Daily News

冠脉内阿昔单抗显示对糖尿病 STEMI 患者有优势

L.A. McKeown

August 11, 2016

News Daily News

Intracoronary Abciximab Shows Advantage in Diabetic STEMI Patients

L.A. McKeown

August 11, 2016

News Daily News

El Abciximab Intracoronario es Beneficioso en Pacientes Diabéticos Víctimas de STEMI

L.A. McKeown

August 11, 2016

Presentation

Intracoronary Abciximab Shows Advantage in Diabetic STEMI Patients

Presenter: Raffaele Piccolo

August 10, 2016

Presentation TCT 2014

Optimal Duration of DAPT After Intracoronary Stenting: Current Status

Presenter: Roxana Mehran

September 13, 2014

News Conference News ESC 2014

IBIS-4: High-Dose Statin Therapy May Reverse Atherosclerosis in STEMI

Todd Neale

September 02, 2014

News Daily News

In-Hospital Switching of Antiplatelet Agents in MI Patients Relatively Common, Driven by Patient Risk, Other Factors

L.A. McKeown

August 20, 2014

Presentation

Intracoronary Thrombolysis in STEMI Patients with Massive Intraluminal Thrombus, Failed Aspiration

Presenter: Daniella Boscarelli

April 10, 2014

News Daily News

STEMI Patients with Large Thrombus Benefit from Low-dose Thrombolysis

Yael L. Maxwell

April 10, 2014

News Daily News

Un Subestudio del AIDA STEMI No Confirma Ventaja alguna para el Abciximab Intracoronario

February 27, 2013

News Daily News

AIDA STEMI Substudy Confirms No Advantage for Intracoronary Abciximab

February 27, 2013

Presentation

Intracoronary Compared with IV Bolus Abciximab Application During Primary PCI in STEMI

Presenter: I. Eitel

February 26, 2013

News Daily News

Study Shows Impact of Public Health Communication on Clopidogrel Use Post DES

November 20, 2012

Presentation TCT 2012

Glycoprotein IIb/IIIa Inhibitors in the Era of Bivalirudin and New Oral Antiplatelet Agents: Is Intracoronary Application the Standard of Choice?

Presenter: Rajesh Dave

October 25, 2012

News Daily News

Stopping Clopidogrel 1 Year After MI Raises Risk in PCI Patients

Jason Kahn

July 20, 2012

News Daily News

La Opción Antitrombótica durante una PCI Influye en los Resultados de los Malos Respondedores al Clopidogrel

Caitlin E. Cox

June 07, 2012

News Daily News

Antithrombotic Choice During PCI Influences Outcomes in Poor Clopidogrel Responders

Caitlin E. Cox

June 07, 2012

News Daily News

Un Meta Análisis Favorece el Abciximab Intracoronario frente al Abciximab Intravenoso en PCI Primarias

June 05, 2012

News Daily News

Meta-analysis Favors Intracoronary vs. Intravenous Abciximab in Primary PCI

June 05, 2012

Presentation

Clinical Impact of Intracoronary Abciximab in Patients Undergoing Primary PCI

Presenter: R. Piccolo

June 04, 2012

Advertisement

冠脉内阿昔单抗显示对糖尿病 STEMI 患者有优势

Intracoronary Abciximab Shows Advantage in Diabetic STEMI Patients

El Abciximab Intracoronario es Beneficioso en Pacientes Diabéticos Víctimas de STEMI

Intracoronary Abciximab Shows Advantage in Diabetic STEMI Patients

Optimal Duration of DAPT After Intracoronary Stenting: Current Status

IBIS-4: High-Dose Statin Therapy May Reverse Atherosclerosis in STEMI

In-Hospital Switching of Antiplatelet Agents in MI Patients Relatively Common, Driven by Patient Risk, Other Factors

Intracoronary Thrombolysis in STEMI Patients with Massive Intraluminal Thrombus, Failed Aspiration

STEMI Patients with Large Thrombus Benefit from Low-dose Thrombolysis

Un Subestudio del AIDA STEMI No Confirma Ventaja alguna para el Abciximab Intracoronario

AIDA STEMI Substudy Confirms No Advantage for Intracoronary Abciximab

Intracoronary Compared with IV Bolus Abciximab Application During Primary PCI in STEMI

Study Shows Impact of Public Health Communication on Clopidogrel Use Post DES

Glycoprotein IIb/IIIa Inhibitors in the Era of Bivalirudin and New Oral Antiplatelet Agents: Is Intracoronary Application the Standard of Choice?

Stopping Clopidogrel 1 Year After MI Raises Risk in PCI Patients

La Opción Antitrombótica durante una PCI Influye en los Resultados de los Malos Respondedores al Clopidogrel

Antithrombotic Choice During PCI Influences Outcomes in Poor Clopidogrel Responders

Un Meta Análisis Favorece el Abciximab Intracoronario frente al Abciximab Intravenoso en PCI Primarias

Meta-analysis Favors Intracoronary vs. Intravenous Abciximab in Primary PCI

Clinical Impact of Intracoronary Abciximab in Patients Undergoing Primary PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content